A Phase 1 Study of ASP2215 in Combination With Induction and Consolidation Chemotherapy in Patients With Newly Diagnosed Acute Myeloid Leukemia

Trial Profile

A Phase 1 Study of ASP2215 in Combination With Induction and Consolidation Chemotherapy in Patients With Newly Diagnosed Acute Myeloid Leukemia

Recruiting
Phase of Trial: Phase I

Latest Information Update: 12 May 2017

At a glance

  • Drugs Gilteritinib (Primary) ; Cytarabine; Idarubicin
  • Indications Acute myeloid leukaemia
  • Focus Adverse reactions
  • Sponsors Astellas Pharma
  • Most Recent Events

    • 04 May 2017 Planned primary completion date changed from 1 Mar 2018 to 18 Aug 2017.
    • 07 Feb 2017 Planned number of patients changed from 21 to 44.
    • 24 Jan 2017 Planned End Date changed from 1 Nov 2018 to 1 Mar 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top